MX9704491A - Composicion que modula la apoptosis, que comprende un factor que influye en la proporcion intracelular de metional o malondialdehido. - Google Patents

Composicion que modula la apoptosis, que comprende un factor que influye en la proporcion intracelular de metional o malondialdehido.

Info

Publication number
MX9704491A
MX9704491A MX9704491A MX9704491A MX9704491A MX 9704491 A MX9704491 A MX 9704491A MX 9704491 A MX9704491 A MX 9704491A MX 9704491 A MX9704491 A MX 9704491A MX 9704491 A MX9704491 A MX 9704491A
Authority
MX
Mexico
Prior art keywords
methional
malondialdehyde
apoptosis
factor affecting
intracellular rate
Prior art date
Application number
MX9704491A
Other languages
English (en)
Other versions
MXPA97004491A (es
Inventor
George Anthony Quash
Alain Doutheau
Original Assignee
Ct Internat De Rech S
Dermatologiques Galerma C I R
Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Internat De Rech S, Dermatologiques Galerma C I R, Galderma filed Critical Ct Internat De Rech S
Publication of MX9704491A publication Critical patent/MX9704491A/es
Publication of MXPA97004491A publication Critical patent/MXPA97004491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se relaciona con un compuesto escogido entre el metional, el malondialdehído y todo factor que influye en la proporcion intracelular del metional o del malondialdehído, para una utilizacion como medicamento. Este medicamento es destinado de manera más particular a modular el fenomeno de la muerte programada de las células (la apoptosis). Se relaciona igualmente, a una composicion farmacéutica o cosmética que modula la apoptosis, caracterizada porque comprende, a modo de agente activo, un compuesto escogido entre el metional, el malondialdehído y todo factor que influye en la proporcion intracelular de metional o de malondialdehído, en combinacion con un portador farmacéutica o cosmetologicamente aceptable. Tiene así, por objeto, un procedimiento para prevenir y/o luchar contra el envejecimiento fotoinducido o cronologico de la piel.
MXPA/A/1997/004491A 1994-12-29 1997-06-17 Composicion que modula la apoptosis, que comprende un factor que influye en la proporcion intracelular de metional o malondialdehido MXPA97004491A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR94/15884 1994-12-29
FR9415884A FR2728790B1 (fr) 1994-12-29 1994-12-29 Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
FR9415884 1994-12-29
PCT/FR1995/001715 WO1996020701A1 (fr) 1994-12-29 1995-12-22 Composition modulant l'apoptose comprenant un facteur influençant le taux intracellulaire de methional ou de malondialdehyde

Publications (2)

Publication Number Publication Date
MX9704491A true MX9704491A (es) 1997-10-31
MXPA97004491A MXPA97004491A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
AU4451296A (en) 1996-07-24
EP0723778B1 (fr) 2000-04-05
ATE191339T1 (de) 2000-04-15
FR2728790A1 (fr) 1996-07-05
DK0723778T3 (da) 2000-07-10
FI972780A0 (fi) 1997-06-27
CA2166243A1 (fr) 1996-06-30
GR3033732T3 (en) 2000-10-31
DE69516107D1 (de) 2000-05-11
KR970706807A (ko) 1997-12-01
IL116586A0 (en) 1996-03-31
DE69516107T2 (de) 2000-11-16
NO973034L (no) 1997-08-29
WO1996020701A1 (fr) 1996-07-11
EP0723778A1 (fr) 1996-07-31
US5744499A (en) 1998-04-28
AU704064B2 (en) 1999-04-15
ZA9511015B (en) 1996-08-12
RU2160103C2 (ru) 2000-12-10
NZ298831A (en) 2001-04-27
AR001783A1 (es) 1997-12-10
FR2728790B1 (fr) 1997-01-24
PL320963A1 (en) 1997-11-24
CA2166243C (fr) 2003-07-01
KR100310499B1 (ko) 2001-12-12
FI972780A (fi) 1997-06-27
BR9510509A (pt) 1998-07-07
HUT77490A (hu) 1998-05-28
JP2000515845A (ja) 2000-11-28
NO973034D0 (no) 1997-06-27
PL182597B1 (pl) 2002-02-28
PT723778E (pt) 2000-09-29
ES2147272T3 (es) 2000-09-01

Similar Documents

Publication Publication Date Title
NO933239D0 (no) Bioeroderbar innretning for administering av aktive ingredienser
KR950700282A (ko) S-트리아진 유도체 및 이를 활성성분으로서 함유하는 에스트로겐-의존성 질환 치료제(s-Triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient)
NO973034L (no) Apoptose-modulerende preparat omfattende en faktor som påvirker det intracellulære nivå av methional eller malondialdehyd
CA2286409A1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
AU2807195A (en) Hair growing agent
IL103920A0 (en) Method and pharmaceutical preparations for inhibiting the growth of cancer cells
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GR3031044T3 (en) Pharmaceutical and/or cosmetic preparation and the use of the preparation
HK1021539A1 (en) Androstene derivatives.
ATE157536T1 (de) Synergistische lichtschutzkombinationen und kosmetische und dermatologische formulierungen, solche kombinationen enthaltend
EP0620004A4 (en) MEDICAL COMPOSITION.
ZA92769B (en) Anti-microbial personal care formulation
DE69314463D1 (de) Hautregenerierende kosmetische zusammensetzung
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
AU3080795A (en) Novel combination product comprising an antifungal agent and crotamiton as an antifungal activity enhancer and dermatological or cosmetic compositions comprising same
ATE168004T1 (de) Juckreizstillendes mittel
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.
EP0489933A4 (en) Bile alcohol and drug containing the same as active ingredient
NO921039D0 (no) Nye aryl-halogenalkylpyrazoler, preparater med herbicid virkning inneholdende forbindelsene som aktiv bestanddel oganvendelse av forbindelsene for bekjempelse av uoensket vegetasjon
AU4982693A (en) Amide compound and plant disease control agent containing the same as active ingredient

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees